Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment

Abstract

We report severe inflammatory ophthalmopathy in a euthyroid patient with non-small-cell lung cancer during nivolumab therapy. The occurrence of such ophthalmic adverse events is likely to increase during nivolumab therapy in patients with advanced malignancies.